drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells); adoptive immunotherapy
drug_description
Autologous T cells engineered with a retroviral vector to express a single bispecific chimeric antigen receptor targeting CD19 and CD22, enabling TCR-independent activation, expansion, cytokine release, and cytotoxic killing of B-lineage leukemia; used to eradicate MRD and induce B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are retrovirally engineered to express a single tandem (bispecific) CAR that recognizes CD19 and CD22 on B-lineage cells. Antigen binding triggers TCR-independent CD3ΞΆ/costimulatory signaling, leading to T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD19+/CD22+ leukemia, resulting in MRD clearance and B-cell aplasia.
drug_name
CD19/CD22 CAR-T cells (autologous, tandem)
nct_id_drug_ref
NCT06752785